FDA Supports Advancement of Roxadustat Trial for Anemia-Associated MDS
Roxadustat’s developers intend to file the full phase 3 protocol to the FDA in the fourth quarter of 2025.
Previous Post
Challenges in Getting Access to an Initial Pediatric Dermatology Appointment: Elizabeth Garcia Creighton
Next Post
Real-World Analysis Shows Growing Use of Octave’s MS Disease Activity Test in Clinical Practice
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago